Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies

Patients with triple-negative breast cancer (TNBC), and those with HR-positive/HER2-negative breast cancer after the development of endocrine resistance, have limited treatment options. Black women are diagnosed more often with TNBC and feel the lack of treatment options more acutely, leading to greater outcomes disparities. Antibody-drug conjugates (ADCs) are novel agents that may improve outcomes for patients. However, clinicians lack the ability to implement them into practice appropriately or may be hesitant to use them altogether. This 90-minute enduring activity is led by a panel of breast cancer experts who will guide participants through a discussion of criteria to select patients to receive ADCs, adverse event (AE) management, and strategies to foster equitable care of patients with metastatic breast cancer (mBC).

Learn more: https://www.ceconcepts.com/activity/transforming-metastatic-breast-cancer-management-harnessing-the-power-of-antibody-drug-conjugate-therapies-2/ 

Download the slides: https://www.ceconcepts.com/wp-content/uploads/2024/08/MM-140—ASCO—240606-1.pdf

Download the Transcript: https://www.ceconcepts.com/wp-content/uploads/2024/08/MMV-140-Transcript_FINAL.pdf